EFFECT OF DISEASE AND DRUG-TREATMENT ON BLOOD SEROTONIN AND MONOAMINE-OXIDASE-B ACTIVITY IN PARKINSONS-DISEASE

被引：4
|
作者：
VANKEMPEN, GMJ [1 ]
JANJUA, R [1 ]
ROOS, RAC [1 ]
机构：
[1] LEIDEN STATE UNIV,ACAD HOSP,DEPT NEUROL,2333 AA LEIDEN,NETHERLANDS
来源：
CLINICAL NEUROLOGY AND NEUROSURGERY | 1995年 / 97卷 / 02期
关键词：
DRUG EFFECTS; 5-HYDROXYTRYPTAMINE; MONOAMINE OXIDASE; PARKINSONS DISEASE; SELEGILINE; SEROTONIN;
D O I：
10.1016/0303-8467(95)00011-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Serotonin (5-hydroxytryptamine, 5HT) content and monoamine oxidase (MAO) activity were determined in whole blood of patients with Parkinson's disease (PD) with and without drug treatment and compared with controls. From that comparison a significant reduction in platelet 5HT became apparent in PD. Selegiline, which was always used in combination with L-dopa, not only inhibited MAO activity, as expected, but it also appeared to induce an increase in 5HT content.
引用
收藏
页码：131 / 133
页数：3
相关论文
共 50 条
  • [21] Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer's and Parkinson's Disease
    Ozdemir, Zeynep
    Alagoz, Mehmet Abdullah
    Bahcecioglu, Omer Faruk
    Gok, Selim
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (29) : 6045 - 6065
  • [22] MITOCHONDRIAL FACTORS INVOLVED IN PARKINSONS-DISEASE BY MPTP TOXICITY IN MACACA-FASCICULARIS AND DRUG EFFECT
    VILLA, RF
    ARNABOLDI, R
    GHIGINI, B
    GORINI, A
    NEUROCHEMICAL RESEARCH, 1992, 17 (11) : 1147 - 1154
  • [23] Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson's disease
    Mathew, Githa Elizabeth
    Oh, Jong Min
    Mohan, Kumar
    Tengli, Anandkumar
    Mathew, Bijo
    Kim, Hoon
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (13): : 4786 - 4794
  • [24] Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects
    Riederer, Peter
    Mueller, Thomas
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (11) : 1751 - 1757
  • [25] Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease
    Muck-Seler, Dorotea
    Presecki, Paola
    Mimica, Ninoslav
    Mustapic, Maja
    Pivac, Nela
    Babic, Ana
    Nedic, Gordana
    Folnegovic-Smalc, Vera
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (07): : 1226 - 1231
  • [26] Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease
    Mazumder, Muhammed Khairujjaman
    Paul, Rajib
    Phukan, Banashree Chetia
    Dutta, Ankumoni
    Chakrabarty, Jayasree
    Bhattacharya, Pallab
    Borah, Anupom
    MEDICAL HYPOTHESES, 2018, 117 : 54 - 58
  • [27] A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease
    Binde, C. D.
    Tvete, I. F.
    Gasemyr, J.
    Natvig, B.
    Klemp, M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (09) : 1917 - 1927
  • [28] Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease
    Mueller, Thomas
    Riederer, Peter
    Gruenblatt, Edna
    CLINICAL NEUROPHARMACOLOGY, 2017, 40 (05) : 208 - 211
  • [29] A dose-ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
    Andreu, N
    DamaseMichel, C
    Senard, JM
    Rascol, O
    Montastruc, JL
    MOVEMENT DISORDERS, 1997, 12 (03) : 293 - 296
  • [30] BENEFICIAL EFFECT OF CABERGOLINE, NEW LONG-LASTING D-2 AGONIST IN THE TREATMENT OF PARKINSONS-DISEASE
    RABEY, JM
    NISSIPEANU, P
    INZELBERG, R
    KORCZYN, AD
    CLINICAL NEUROPHARMACOLOGY, 1994, 17 (03) : 286 - 293
12345